Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Melanoma: early-phase trial registry
89 of 269 indexed Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #36 of 28,707 conditions by registered trial count.
269 US clinical trials · 89 currently recruiting · #36 of 28,707 conditions by registered trial count
Melanoma: 269 US clinical trials tracked, 89 recruiting.
Melanoma is the subject of 269 registered US clinical trials on ClinicalTrials.gov, 89 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 184 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 20 of these trials.
Enrollment posture brief
Registry condition melanoma
OPEN 89 | RECR 33% | LATE 19 | EARLY 184 | RANK #36 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Melanoma lists 89 open slots (33% of 269 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Melanoma is recruiting below its size-band peers.
89 of 269 indexed trials (33.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Melanoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 20 of 269 trials (7.4%). 139 distinct sponsors appear on at least one study for this condition label.
-
Typical Melanoma enrolment sits around 72 participants.
Median target enrolment is 72 among the 267 trials that report a genuine target (sentinel values excluded). 155 of those (58.1%) plan for fewer than 100 participants.
-
Melanoma research is mostly interventional.
231 interventional and 38 observational studies make up this index (85.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
269 total, page 3 of 6
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
Amgen
NCT06054555
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Bristol-Myers Squibb
NCT05625399
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
Asher Biotherapeutics
NCT05653882
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT02568267
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Pierre Fabre Medicament
NCT04913285
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
NCT04083599
A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma
Sandoz
NCT06153238
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
BioAtla
NCT05180799
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
Merck Sharp & Dohme
NCT04305054
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences
NCT04198766
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
ModernaTX
NCT03897881
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
Pfizer
NCT04657991
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group
NCT03611868
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
Memorial Sloan Kettering Cancer Center
NCT01223248
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
AstraZeneca
NCT05061134
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
University of California, Davis
NCT04478318
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
iTeos Belgium
NCT05060432
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Regeneron Pharmaceuticals
NCT06190951
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Merck Sharp & Dohme
NCT06099782
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
NCT00600496
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries
NCT03872947
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors
ENB Therapeutics
NCT04205227
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Novartis Pharmaceuticals
NCT04417621
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
NCT04899908
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Uswm CT
NCT04044859
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
NCT06101134
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Novartis Pharmaceuticals
NCT03891953
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
NCT01366144
Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma
University of Colorado, Denver
NCT05520294
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05789069
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
NCT06521567
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
University of Oklahoma
NCT05863052
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT05238883
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Adaptimmune
NCT03132922
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
NCT03999749
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
Dan Zandberg
NCT04074967
Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies
ImaginAb
NCT05013099
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
University of Chicago
NCT02743819
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Abramson Cancer Center at Penn Medicine
NCT04013854
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Genentech
NCT04835805
Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
Abramson Cancer Center at Penn Medicine
NCT03757689
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
M.D. Anderson Cancer Center
NCT04407247
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Memorial Sloan Kettering Cancer Center
NCT05912244
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio
NCT03228667
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
Massachusetts General Hospital
NCT06146920
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
NCT03336606
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2
Milton S. Hershey Medical Center
NCT06384417
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
NCT02668770
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
Memorial Sloan Kettering Cancer Center
NCT05289193
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 117 |
| Phase 2 | 67 |
| Phase 3 | 16 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Melanoma page
269 registered trials, 89 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 89 Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Melanoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Melanoma condition card totals 269 registered trials; most-linked intervention Ipilimumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.